Rituxan Hycela to Prevent Immune-Related Adverse Events in Advanced Melanoma Patients Receiving Nivolumab and Ipilimumab

Phase 2, randomised, open-label trial in melanoma comparing Arm A (standard of care) with Arm B (rituximab, hyaluronidase human) (2 arms). Primary endpoint: Number of Participants With Common Terminology Criteria (CTC) (Version [v]5.0) Grade 3 or Greater Immune-related Adverse Events at 6 months. Started Jun 2019; status: completed.